

LIST OF FIGURES

Figure No.	Title	Page No.
1.1	Natural history of development of peptic ulcer disease and gastric carcinoma	13
1.2	Biopsy sample of colon ulcer showing occurrence of <i>H. pylori</i>	17
1.3	Virulence factors of <i>H. pylori</i> that aid in stomach infection	18
2.1	Mode of action of bacteriocins against cytoplasmic membrane	24
2.2	Pathological changes in gastric epithelium upon <i>H. pylori</i> infection	58
2.3	Genetic organization of <i>cag</i> pathogenicity island (PAI)	60
2.4	Constitution of type IV secretory apparatus and pathophysiology of <i>H. pylori</i> infection	61
2.5	Modulation of enzyme activities (arginase, CAT2, iNOS, ODC) and NO production during acute and chronic gastritis	64
2.6	Mechanism of <i>H. pylori</i> inhibition by probiotic lactic acid bacteria	72
3.1	Graphical representation of adsorption-desorption method of bacteriocin purification	108
3.2	Schematic representation of <i>in vivo</i> <i>H. pylori</i> inhibition assay	137
4.1	Tetrad clusters of isolates, (a) at 10X magnification; (b) at 40X magnification	143
4.2	16S rRNA gene sequence of <i>Pediococcus acidilactici</i> BA28 (GenBank accession no. JX431046)	151
4.3	Phylogenetic relationship of <i>P. acidilactici</i> BA28 partial 16S rRNA gene sequence	153
4.4a	Figure showing i) growth curve of <i>Pediococcus acidilactici</i> BA28; ii) variation in pH w.r.t. incubation time	155
4.4b	Figure showing bacteriocin activity of <i>Pediococcus acidilactici</i> BA28 w.r.t. incubation time	156
4.5	Well diffusion assay showing growth inhibition in indicator lawn (<i>P. acidilactici</i> LB42); where 1-0 h; 2-4 h; 3-8 h; 4-12 h; 5-16 h; 6-20 h; 7-22	156

	h; 8-24 h samples	
4.6	Standard curve of protein	157
4.7	Well diffusion assay plate showing pediocin activity in runs 1, 2, 4, 5, 6, 7 and 8	161
4.8	Well diffusion assay plate showing pediocin activity in CCRD runs 1 to 20 where, c-control	163
4.9	Response surfaces of pediocin production by <i>Pediococcus acidilactici</i> BA28 estimated by zone of inhibition; (A) as function of peptone and beef extract; (B) as function of pH and peptone; (C) as function of pH 6 and beef extract	164
4.10	Comparison of (A) growth pattern; (B) specific activity of <i>Pediococcus acidilactici</i> BA28 on MRS and RSM optimized media	167
4.11	Thermostability of pediocin BA28	169
4.12	Sensitivity of bacteriocin BA28 to pH changes	170
4.13	Storage stability of bacteriocin BA28 at -20 °C	174
4.14	Analysis of purified bacteriocin BA28 on silver stained 20% SDS-PAGE; Lane 1: band of purified bacteriocin; Lane 2: 6.5 KDa to 43 KDa protein ladder (Bangalore Genei)	175
4.15	C-18 Reverse phase chromatogram of purified pediocin BA28	176
4.16	MALDI-TOF spectrum of purified pediocin BA28	177
4.17	Growth inhibition in indicator lawn, (a) Disc diffusion assay plate in which spots 1, 2, 3, 4, 7, 8, 9 shows bacteriocin activity; (b) Well-diffusion assay plate in which wells 3-10 shows bacteriocin activity	183
4.18	Growth inhibition of <i>H. pylori</i> (a) disc diffusion assay plate; (b) Well-diffusion assay plate showing bacteriocin activity	186
4.19	Residual bacteriocin activity in pasteurized milk sample	187
4.20	Residual bacteriocin activity in vegetables fresh cuts	189
4.21	Residual bacteriocin activity in moong sprouts sample	191
4.22	Residual bacteriocin activity in channa sprouts sample	193
4.23	Residual bacteriocin activity in minced meat sample	195
4.24	Analysis of plasmid on 1% agarose gel; Lane 1: Supercoiled DNA ruler (Bangalore Genei); Lane 2: Plasmid from <i>P. acidilactici</i> BA28; Lane 3:	201

	Cured sample of <i>P. acidilactici</i> BA28	
4.25	Effect of ethidium bromide on the viability of <i>P. acidilactici</i> BA28	202
4.26	Analysis of cured derivative by disc diffusion assay; 1-2- cured isolate; 3-5- native <i>P. acidilactici</i> BA28	203
4.27	Antibiogram of A), B) wild type and C), D) cured <i>P. acidilactici</i> BA28	205
4.28	Analysis of PCR product on 1.5% agarose gel; Lane 1: Prefect DNA ladder (Novagen); Lane 2: PCR product of 618bp	206
4.29	Sequence of 618bp product of partial ped operon from plasmid of <i>P. acidilactici</i> BA28	207
4.30	Nucleotide sequence and predicted amino acid sequences of the 618 bp stretch of partial ped operon of plasmid	210
4.31	Multiple sequence alignment of pediocin using clustal omega	212
4.32	<i>In vitro</i> growth inhibition of <i>H. pylori</i> by pediocin BA28 in terms of log cfu/ml	215
4.33	<i>In vitro</i> growth inhibition of <i>H. pylori</i> by pediocin BA28 in terms of absorbance	216
4.34	Scanning electron micrographs of bacteriocin-treated <i>H. pylori</i>	217
4.35	Bacterial counts in stool samples of experimental animals	219
4.36a	Histopathologic evaluation of antral gastric samples of mice (Hematoxylin and Eosin stained; magnification X100) where; (A) normal mucosa in control group mice, (B) chronic gastritis, necrosis of cells, mucosal damage due to the enzymes released by inflammatory cells+ with lymphocytic predominance, (C) acute inflammation, mononuclear and PMNLs migration and proliferation with necrotic debris, (D) epithelial disruption with necrotic base and neutrophilic infiltration, (E) peptic ulcer and (F) healing by fibrosis after giving treatment with <i>P. acidilactici</i> BA28	220
4.36b	Histopathologic evaluation of antral gastric samples of mice (Grey scale)	221
4.37	Gross specimens of mice stomach showing different stages of peptic ulcers; (A) early stage, (B) middle stage and (C) chronic stage	221

LIST OF TABLES

Table No.	Title	Page No.
1.1	Taxonomic status of <i>H. pylori</i>	16
2.1	Properties of various bacteriocin classes	36
2.2	Antimicrobial spectrum of bacteriocins	47
2.3	Virulence and maintenance factors of <i>Helicobacter pylori</i>	57
2.4	Detection of <i>Helicobacter pylori</i> infection in humans	66
2.5	Recommended treatment regimens for <i>H. pylori</i> infection	67
2.6	Probiotic cultures used to treat <i>H. pylori</i> infections	71
2.7	Anti- <i>Helicobacter pylori</i> bacteriocins	74
2.8	Use of bacteriocinogenic protective cultures to control <i>Listerial</i> spoilage in meat products	78
3.1	Composition of Brain Heart Infusion Medium (BHI)	82
3.2	Composition of Cooked Meat Media (CMM)	83
3.3	Composition of EMB agar (Eosin Methylene Blue Agar)	84
3.4	Composition of <i>Listeria</i> Enrichment Broth	84
3.5	Composition of Luria Broth (LB)	85
3.6	Composition of MRS medium (de Man's Rogosa Sharpe Medium)	86
3.7	Composition of Nutrient Agar (NA)	86
3.8	Composition of Rapport Vassiliadis <i>Salmonella</i> Enrichment Broth	87
3.9	Composition of Reinforced Medium for <i>Clostridia</i>	88
3.10	Composition of SS HiVeg Agar (<i>Salmonella Shigella</i> HiVeg Agar)	88

3.11	Composition of Yeast Extract Peptone Dextrose Media	89
3.12	Growth media and conditions of indicator microorganisms	91
3.13	Experimental design of Plackett Burman matrix	104
3.14	Experimental design of CCRD matrix	105
3.15	Composition of 20% resolving gel mixture	113
3.16	Composition of fixative	113
3.17	Test systems adopted for biopreservative assays	121
3.18	List of antibiotics used for the study	129
3.19	Composition of PCR reaction mixture	132
3.20	Optimized PCR thermal profile for partial <i>ped</i> operon of plasmid	132
4.1	Summary of the morphological properties of lactic acid bacterial isolates	144
4.2	Summary of the physical growth parameters of selected LAB isolates	147
4.3	Summary of the physiological properties of lactic acid bacterial isolates	150
4.4	BLASTn results showing sequence similarity of 16S rRNA nucleotide sequence of <i>P. acidilactici</i> BA28	152
4.5	Experimental design and responses of Plackett Burman matrix	160
4.6	Experimental design and bacteriocin responses of CCRD matrix	162
4.7	Analysis of variance among bacteriocin responses	165
4.8	Final composition of optimized media	166
4.9	Purification of bacteriocin BA28 by adsorption desorption method	168
4.10	Sensitivity of bacteriocin BA28 to various enzymes	171
4.11	Sensitivity of bacteriocin BA28 to various organic solvents	172
4.12	Sensitivity of bacteriocin BA28 to various denaturation agents	173
4.13(a)	Antimicrobial spectrum of human LAB isolates against Gram-positive	178

	pathogenic indicator strains	
4.13(b)	Antimicrobial spectrum of human LAB isolates against Gram-negative pathogenic indicator strains	180
4.13(c)	Antimicrobial spectrum of human LAB isolates against Yeast and Non-pathogenic indicator strains	182
4.14	Microbial counts (\log_{10} cfu/ml) in pasteurized milk sample	188
4.15	Microbial counts (\log_{10} cfu/ml) in vegetables fresh cuts	190
4.16	Microbial counts (\log_{10} cfu/ml) in moong sprouts	192
4.17	Microbial counts (\log_{10} cfu/ml) in channa sprouts sample	194
4.18	Microbial counts (\log_{10} cfu/ml) in minced meat sample	196
4.19	Inhibition of bacteriocin producing <i>P. acidilactici</i> BA28 by various antibiotics	204
4.20	BLASTn results showing sequence similarity of partial ped operon (618 bp) of plasmid	208
4.21	BLASTp result showing sequence similarity of partial ped operon (618 bp) of plasmid	211